Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

NicOx On Track For First-Quarter 2009 Naproxcinod Filing

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

French firm aims to become a fully integrated biopharma within three years, with commercial operations in the U.S. and major EU countries.

You may also be interested in...



NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod

In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.

NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod

In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.

NicOx Adds Two Blood Pressure Monitoring Studies To Naproxcinod Program

Results of both blood pressure studies and two Phase III trials expected in 2008, positioning naproxcinod for mid-2009 filing.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS066714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By